Navigation Links
Acorda Therapeutics submits new drug application for Fampridine-SR in multiple sclerosis
Date:2/2/2009

HAWTHORNE, N.Y., February 2, 2009 Acorda Therapeutics, Inc. (Nasdaq: ACOR) today announced the submission of a New Drug Application to the U.S. Food and Drug Administration (FDA) on January 30, 2009 for Fampridine-SR, a novel therapy being developed to improve walking ability in people with multiple sclerosis (MS). The Company expects that the NDA filing, if accepted, will be subject to standard review, which would provide a target for the FDA to complete its review within ten months from receipt of the submission.

"This NDA filing is a major milestone for Acorda and our Fampridine-SR development program," said Acorda Therapeutics President and CEO Ron Cohen, M.D. "Walking impairment is one of the most pervasive and alarming aspects of MS for patients, their families and their health care providers. There are no medicines currently indicated to improve walking ability in people with MS, and Fampridine-SR therefore may represent an important new approach to MS therapy. We are excited to have taken this major step toward potentially making Fampridine-SR available to help people with MS."

Approximately 400,000-500,000 people in the Unites States have MS, and recent studies indicate that between 64-85% of people with MS have walking disability1,2. Fully 70% of people with MS who have walking disability report it to be the most challenging aspect of their disease1.

The Fampridine-SR NDA submission is based on data from a comprehensive development program assessing the safety and efficacy of Fampridine-SR, including two Phase 3 trials that involved 540 people with MS and were conducted under Special Protocol Assessments (SPAs) from the FDA. The safety and efficacy profile of Fampridine-SR was consistent across Phase 2 and Phase 3 trials. Overall, the NDA filing included more that 50 clinical studies of Fampridine-SR. The total exposure to Fampridine-SR in MS studies filed as part of the NDA was over 1,200 patient-years. Additionally, more than 450 people are currently enrolled in Fampridine-SR extension trials, with treatment duration ranging from seven months to almost five years.

The Company also has discussed Fampridine-SR with regulatory authorities in Europe and believes that the current data are sufficient to file a centralized Marketing Authorization Application (MAA) with the European Medicines Agency (EMEA). The Company plans to file the MAA when it has determined the commercialization pathway that maximizes the value of Fampridine-SR outside the U.S.


'/>"/>

Contact: Jeff MacDonald
jmacdonald@acorda.com
914-347-4300
Ruder Finn Public Relations
Source:Eurekalert

Related biology news :

1. A novel target for therapeutics against Staph infection
2. Bayhill Therapeutics and the Juvenile Diabetes Research Foundation announce research collaboration
3. Growing fuel and medicine: Advancing biofuels and plant-produced therapeutics
4. Sirtris review of sirtuin therapeutics for diseases of aging in Nature Reviews Drug Discovery
5. Media invitation: 20th EORTC-NCI-ACR Symposium on Molecular Targets and Cancer Therapeutics
6. CU-Boulder, biotech firm team up on python project in search for human cardiac therapeutics
7. Michael J. Fox Foundation PD Therapeutics Conference
8. Galapagos and Cystic Fibrosis Foundation Therapeutics announce drug discovery collaboration
9. ORNL supercomputer simulation wins prize for fastest-running science application
10. Track your fitness, environmental impact with new cell phone applications
11. New filtering technology has environmental, industrial applications
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/15/2016)... FREMONT, Calif. , Dec. 15, 2016   ... a publicly held genomics technology company, announced today that ... the Listing Qualifications Department of The Nasdaq Stock Market ... the closing bid price of WaferGen,s common stock had ... days.  Accordingly, WaferGen has regained compliance with Listing Rule ...
(Date:12/15/2016)... LONDON , Dec. 15, 2016 /PRNewswire/ ... the driving experience, health wellness and wellbeing ... As one in three new passenger vehicles ... voice recognition, gesture recognition, heart beat monitoring, ... eyelid monitoring, facial monitoring, and pulse detection. ...
(Date:12/15/2016)... "Increase in mobile transactions is driving the growth of ... expected to grow from USD 4.03 billion in 2015 ... of 29.3% between 2016 and 2022. The market is ... smart devices, government initiatives, and increasing penetration of e-commerce ... to grow at a high rate during the forecast ...
Breaking Biology News(10 mins):
(Date:1/16/2017)... 2017   Valentin A. Pavlov, PhD , associate ... and CEO of The Feinstein Institute for Medical ... how the nervous system regulates the immune system, which ... medicine devices to treat disease and injury. The ... The paper examines various studies which further ...
(Date:1/13/2017)... 2017 Research and Markets has announced the ... Global Forecast to 2021" report to their offering. ... The biosimilars market is ... Billion in 2016, at a CAGR of 26.3%. ... manufacturing type, and application. Factors such as rising incidence of various ...
(Date:1/12/2017)... ... January 12, 2017 , ... MEXICO’S FIRST ... Inc., announces the successful outcome of the first lumbar fusion procedure in ... Technologies, Inc.) has partnered with Mexico-based medical product company BioMedical Technologies to ...
(Date:1/12/2017)... , January 12, 2017 The ... world,s biggest facility for producing mycorrhizae. The Centre for ... tapping potential of mycorrhizae and developed a technology that ... ... The TERI facility has a ...
Breaking Biology Technology: